Extracranial and Diffuse Bone Marrow Metastases from Anaplastic Oligodendroglioma: A Case Report and Review of the Literature

Evangelia Razis†
Avraam Assi†
Albert Huang†
Georgios Rigakos†
Sotirios Papadopoulos†
Savvas Papadopoulos‡
Efimia Vrakidou§
Constantinos Dardoufas∥
Christos Mourmouris¶
Stefanos Lampropoulos†
Panagiotis Nomikos∥

1Third Department of Medical Oncology (A.A, A.H, G.R, So.P, S.L and E.R)
2Pathology Department (Sav.P)
3Hematology Department (E.V)
4Radiation Oncology Department (C.D)
5Radiology Department (C.M)
6Neurosurgery Department (P.N), Hygeia Hospital, 4 Erythrou Stavrou Str.
& Kifisias Av. 151 23 Marousi, Athens, Greece

Abstract
Extracranial metastases from anaplastic oligodendroglioma are very rare. We present a 53 year old male patient who developed extracranial progression and bone marrow metastases from anaplastic oligodendroglioma nearly nine years from the primary diagnosis. He presented with sudden deterioration of consciousness, lethargy, left periorbital swelling and thrombocytopenia, and underwent an MRI of the brain which revealed a left frontal lesion protruding through the orbital cavity impinging on the eye ball. The lesion was subsequently resected, and the histology revealed progression into an anaplastic oligodendroglioma. Furthermore, the patient developed pancytopenia and iliac crest bone marrow biopsy was diagnostic for metastatic, immunohistochemically confirmed anaplastic oligodendroglioma.

Keywords: Oligodendroglioma, Anaplastic, Extracranial, Metastasis, Pancytopenia.

Introduction
Oligodendrogliomas are defined as tumors consisting primarily of neoplastic oligodendrocytes and comprise 1.1% of all primary brain tumors. Their highest incidence occurs between the third and fifth decades of life with a median age at diagnosis of 43 years, although they have also been reported in children and adolescents. The most common sites of location are the frontal and temporal lobes [1]. Oligodendrogliomas may remain silent for many years with the most common presenting symptoms at the time of diagnosis being headache, seizure and focal neurologic deficits. As tumors progress, symptoms vary based on tumor location, size, and rate of tumor growth. Oligodendrogliomas can be divided further into low-grade and anaplastic, the latter characterized by high cellularity, conspicuous cytologic atypia, mitotic activity and, in some cases, microvascular proliferation and necrosis (Grade III). Compared with astrocytic tumors, oligodendroglial tumors more often harbor favorable molecular markers, such as co-deletion of the chromosome arms 1p and 19q and mutations in isocitrate dehydrogenase (IDH). Usually, they spread by local growth and infiltration. Extracranial metastasis is very rare, despite its malignant nature. In a review of 116 patients with extracranial metastases from primary brain tumors, only 7 were caused by oligodendrogliomas (5.25%) [2].
The most frequent metastatic site is bone and bone marrow followed by lymph nodes, liver, lung and scalp [3, 4, 6]. Furthermore, the median time to diagnosis of extracranial metastasis is 34 months and the median survival from the initial diagnosis is 51 months respectively [5]. So far, the exact pathogenic mechanisms implicated in the development of extracranial dissemination remain ill-defined. We report a case of anaplastic oligodendroglioma that progressed extracranially and metastasized to the bone with diffuse bone marrow infiltration.

Case report

A 53 year old man presented with epileptic crises in February 2013. He had been diagnosed with oligodendroglioma in 2004 for which he had had multiple craniotomies and radio/chemotherapy cycles with local recurrences and remissions. In December 2012, resection of a left frontotemporal lesion was performed which revealed relapse of anaplastic oligodendroglioma. The molecular analysis revealed 1p19q co-deletion, IDH1 mutation and MGMT (O\(^6\)-methylguanine-DNA methyltransferase) promoter methylation. Adjuvant radiotherapy and chemotherapy consisting of Procarbazine, lomustine and Vincristine (PCV regimen) were administered, followed by an MRI in May 2013 showing abnormal contrast uptake in the margins of the excised tumor located in the left frontal lobe. Physical examination in July 2013 revealed diminished concentration and left periorbital swelling. A brain MRI showed progression with a left frontal lesion protruding through the orbital cavity invading the orbital fossa. Craniotomy and gross total resection of the lesion followed on September 13, 2013.

Upon macroscopic examination of the material there were 3 tissue specimens measuring together 5.5 x 3.5 cm. These were partially covered by fibroid tissue, partially solid grayish-white and hemorrhagic on the cut surface. The diagnosis was anaplastic oligodendroglioma with neoplastic infiltration of the bone forming the orbital fossa. Tumor cells were hypercellular with intense pleomorphism, vacuolated background, high mitotic activity and nuclear atypia, with areas of microvascular proliferation and necrosis. Immunohistochemically the tumor cells were strongly positive for epidermal growth factor receptor (EGFR) and P53, with focal expression of the glial fibrillary acidic protein (GFAP) and MIB1 (Mindbomb E3 Ubiquitin Protein Ligase-1) positivity in more than 50% of the tumor cells consistent with a high proliferative rate.

The patient left the hospital in a much better condition, but he deteriorated again a few days later. He was re-admitted in October 2013 for lethargy and swelling in his left eye resulting in exophthalmos. A new MRI of the brain showed relapse once again with a lesion extending from the left cranial fossa to the sphenoid sinus and the left orbital fissure (Figure 1). He started treatment with systemic therapy consisting of Bevacizumab 10mg/kg every 14 days along with Volumetric Modulated Arc Radiotherapy (VMAT), a total dose of 38.5 Gy over 11 days.

In the meantime, gradually progressing bilateral muscle weakness of the lower extremities developed, leading eventually to paraplegia and the patient was admitted for further evaluation. At this point, an MRI of the thoracic and lumbar spine showed diffuse abnormal signal intensity in all the thoracic and lumbar vertebrae, with an epidural lesion at the level of the 4th and 5th thoracic and the 5th lumbar vertebrae, causing spinal cord compression (Figure 2). A CT guided fine needle aspiration confirmed metastatic anaplastic oligodendroglioma. Neurological work up confirmed cord compression as the cause of paraplegia.

In addition, progressively worsening pancytopenia of prolonged duration, led us to perform a diagnostic bone marrow aspiration in November 2013 which yielded a “dry tap” but the associated bone marrow biopsy revealed replacement of the myeloid spaces by the neural neoplasm.
Immunohistochemically, the tumor cells were positive for glial fibrillary acidic protein (GFAP), tumor protein p53, synaptophysin and S100 protein, while being negative for cytokeratin-8 (CK8), Wilms tumor protein (WT1), human melanoma black protein-45 (HMB45), epidermal growth factor receptor (EGFR), cluster of differentiation protein-34 (CD34), cluster of differentiation protein-138(CD138) and myeloperoxidase staining. The Ki-67 labelling index was 10–15%.

Consequently, the patient started radiotherapy to the thoracic spine (30 Gy delivered over 11 days) and continued with Bevacizumab in a dose of 15mg/kg every 3 weeks. Unfortunately, lower extremity motor strength was not recovered, and he was transferred home for palliative care.

Eventually, the patient’s general condition and neurological status deteriorated. He died of tumor progression 9 ¼ years after the original diagnosis.

Discussion

Extra neural metastasis from oligodendroglioma is an extremely rare event with only a few cases reported worldwide. A systematic review of the literature found a total of 38 papers reporting 47 cases of bony metastasis from oligodendrogliomas between 1951 and 2017 [3,4,6-42].

Despite the continuous advances in the fields of pathology and molecular biology in the previous decades, the exact mechanisms involved in the spread of extracranial metastases remain ill-defined.

Oligodendrogliomas are the least likely to metastasize among different types of neural tumors. A review of 116 glioma cases in the literature showed that the most common metastasizing tumor type was glioblastoma multiforme (41.4%) followed by medulloblastoma (26.7%), ependymoma (16.4%), astrocytoma (10.3%) and finally oligodendroglioma (5.25%) [2].

The combined analysis of 32 cases of metastatic oligodendrogliomas showed that the most frequent metastatic site was bone and bone marrow (97%), followed by lymph nodes (33%) [3,4,6].

The possible mechanisms involved in the process of metastasis indicate hematologic and lymphatic routes of transmission, though a cerebrospinal fluid route could also be involved [2,9,43].

It has been observed that distant metastases follow craniotomy in the majority of cases. According to this analysis nearly 96% of extracranial metastases have occurred after surgical excision of the primary tumor, suggesting infiltration of tumor cells into surgical defects and extracranial blood vessels [2]. Craniotomy breaches the brain’s innate defense systems, enabling tumor cells to gain entry to both the meningeal and the vertebral venous systems. Furthermore, in some cases, tumor cells may progress extracranially through mechanical escape routes such as ventriculoatrial shunts [44].

So far, 3 distinct patterns of metastatic spread in oligodendrogliomas have been recognized. Macdonald et al detected 2 distinct patterns of metastatic spread. Pattern 1 is characterized by local spread first appearing in the surrounding scalp and in ipsilateral cervical lymph nodes after multiple craniotomies. The tumor may subsequently disseminate to other organs. In pattern 2, patients present with multiple bone metastases at the outset after craniotomy and failure of multimodal therapy with no evidence of initial local or regional spread [14]. A third pattern has been added by Garner et al in which cerebrospinal fluid is the route of spread resulting in intradural deposits [18].

Although the above observations potentially explain the incidence of extraneural dissemination in cases where mechanical defects take place, the access to extraneural sites is not enough to produce metastasis. The role of local factors in the host organ must also be important, further allowing its colonization from tumor cells.

On the other hand, distant metastases have also been observed in cases where no craniotomies had been performed [16]. The reported cases of spontaneous metastatic spread and the overall rarity of the metastatic incidence render the exact mechanisms obscure. Several initial theories trying to explain why metastases are so uncommon have been generally discredited. These include inability of neural tissue to grow outside of the central nervous system, lack of lymphatics in the brain and collapse of thin-walled cerebral veins by advancing tumor [45]. It has been postulated that the absence of intracranial lymphatic vessels poses a significant barrier to tumor spread, while the intracerebral veins are thin walled or encased in dura and therefore collapse ahead of advancing tumor [46]. The idea that brain tumors present earlier and progress to death faster, thus allowing less time for the development of metastases tends to be more accepted nowadays [6,18,47]. It is suggested that metastatic deposits are probably a late event in the natural history of high grade gliomas.

Another theory suggested by Pansera suggests that as the brain parenchyma has little connective tissue stroma, metastatic clones are not selected for their ability to invade fibrous connective tissue and so they are incapable of growing extracranially [48].

In our case, the possible route for infiltration of the bone forming the left orbital fissure could be attributed to the previous craniotomies. Our patient fits well in the 1st pattern described from Macdonald et al in which bone and bone marrow dissemination follows local spread of the tumor in the surrounding scalp near the previous craniotomy. Of note had we been more aware of the rare cases of metastases, we might have detected these earlier thus preventing him from becoming paraplegic. Thus, we publish this case because we feel that the neuro-oncologic community needs to be aware of this possibility. Additionally, we emphasize the necessity of bone marrow biopsy in oligodendroglioma patients experiencing prolonged or profound hematologic toxicity (Figure 3,4).

Conclusion

We reported a case of anaplastic oligodendroglioma with extracranial progression and bone marrow metastases nearly nine years from the initial diagnosis. To our knowledge this is one of few case reports reported in the literature. The exact mechanisms through which extracranial progression occurs remain obscure although disruption of the normal brain barriers through surgical intervention or cerebrospinal fluid, vascular
and lymphatic escape seems to play a significant role in the metastatic process.

Conflict of Interest statement

Each author certifies that he or she has no commercial associations (eg, consultancies, stock ownership, equity interest, patent/licensing arrangements, etc) that might pose a conflict of interest in connection with the submitted article.

Funding statement

The authors certify that the submitted article was not supported neither related to any kind of funding.

References
